



ISSN: 0975-833X

## RESEARCH ARTICLE

### SERUM HEPcidIN AND INTERLEUKIN-6 LEVELS IN ISCHEMIC STROKE

<sup>1</sup>Petrova, J., <sup>2,\*</sup>Manolov, V., <sup>3</sup>Vasilev, V., <sup>4</sup>Tzatchev, K. and <sup>5</sup>Marinov, B.

<sup>1</sup>Department of Neurology, Medical University, Sofia, Bulgaria

<sup>2</sup>Department of Medical Genetics, Medical University, Sofia, Bulgaria

<sup>3</sup>Department of Clinical Laboratory and Clinical Immunology, Medical University, Sofia, Bulgaria

<sup>4</sup>University Hospital "Maichin Dom", Sofia, Bulgaria

#### ARTICLE INFO

##### Article History:

Received 19<sup>th</sup> January, 2015

Received in revised form

06<sup>th</sup> February, 2015

Accepted 15<sup>th</sup> March, 2015

Published online 28<sup>th</sup> April, 2015

##### Key words:

Hepcidin,  
Iron,  
Ischemic stroke,  
Interleukin-6,  
Ferritin.

#### ABSTRACT

**Aim:** Increased hypoxia inducible factors leads to an oxidative stress, which plays an important role in neuronal injuries caused by cerebral ischemia. The free iron in human organism increases significantly during ischemia and is responsible for oxidative damage in the brain. We aimed to evaluate serum hepcidin levels in patients with ischemic stroke and connect expected levels to interleukin-6 concentration.

**Data:** We quantify serum hepcidin levels using ELISA assay in 43 patients with acute ischemic stroke. The samples were taken in the "Aleksandrovska" hospital, Department of Neurology for a period 2013 – 2014 year. We measure serum iron levels (AAS), IL-6 (CLIA) and ferritin (ECLIA) concentration. Results were compared to a control group from previous studies.

**Results:** We found significant elevated serum hepcidin levels in patients with acute ischemic stroke  $79.8 \pm 10.9 \mu\text{g/L}$  compared to the control group  $22.4 \pm 3.9 \mu\text{g/L}$  ( $P < 0.001$ ). Serum IL-6 levels showed significant differences between the groups: control group:  $2.6 \pm 1.1 \text{ ng/L}$  to patients with ischemic stroke  $19.9 \pm 2.1 \text{ ng/L}$  ( $P < 0.001$ ).

**Conclusions:** Our results indicate that serum iron and hepcidin levels are a part of etiology of cerebral ischemia.

Copyright © 2015 Petrova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### INTRODUCTION

The hypoxia inducible factor-1 (HIF) rises erythropoietin, downregulates hepcidin, and induces ferroportin. In human volunteers exposed to high-altitude hypoxia for a few days, ferroportin messenger ribonucleic acid synthesis increases more than 6-fold (Robach *et al.*, 2007). Hepcidin has been proposed as a risk factor for atherosclerosis (Sullivan, 2007), and there is recent evidence supporting this possibility (Valenti, 2009). Low hepcidin production combined with increased ferroportin synthesis strongly favors release of iron from reticuloendothelial storage sites and thus supports a shift of endogenous iron from storage to new red blood cell hemoglobin. Oxidative stress plays an important role in neuronal injuries caused by cerebral ischemia. It is known that free iron increases significantly during ischemia and is responsible for oxidative damage in the brain. Many mechanisms are involved in ischemia-induced brain injuries, such as oxidative stress (Aki *et al.*, 2009), increased intracellular calcium concentration (Tacchini *et al.*, 2008), inflammation (Amantea *et al.*, 2010), and elevated excitatory amino acids (Jia *et al.*, 2009). Iron, the most abundant trace

metal in the brain, is also believed to play a critical role in neuronal injuries caused by oxidative stress in ischemia, although the exact mechanism is not understood. Increased levels of free iron and ferritin have been observed in ischemic brain (Viatte *et al.*, 2005). Elevated hypoxia inducible factor 1 (HIF-1) expression causes high secretion of hepcidin (Nicolas *et al.*, 2002). Elevated serum hepcidin levels lead to internalization and degradation of the only known intracellular iron exporter ferroportin (Nemeth *et al.*, 2004). Increased hepcidin levels causes iron retention in macrophages, hepatocytes and duodenal enterocytes (Zhang *et al.*, 2009). New studies suggest that ferroportin is also expressed in the brain and might play a role in iron export from nerve cells (Moos *et al.*, 2007). In the brain, iron homeostasis depends on both iron uptake by the cells and iron export from the cell.

#### MATERIALS AND METHODS

For a period of one year and a half we determined serum hepcidin levels using ELISA assay in 43 patients with ischemic stroke, (average age  $57.4 \pm 3.9$ ), diagnosed in "Aleksandrovska" hospital, Dept. of Neurology. Their results were compared to age matched 39 controls. We measure serum iron levels, ferritin and IL-6. Pearson's coefficient and

\*Corresponding author: Manolov, V.

Department of Medical Genetics, Medical University, Sofia, Bulgaria.

Student's t-test were used for evaluation of correlation and statistical significance. We quantify hepcidin levels using verified ELISA method (Manolov *et al.*, 2014). For iron quantification we used AAS (Perkin Elmer) and for serum ferritin levels – ECLIA method (Roche Diagnostics). IL-6 was measured by ELISA method. Patients were signing the informed consent according to the Declaration of Helsinki (Directive 2001/20 / EC).

## RESULTS

We found significant elevated serum hepcidin levels in patients with acute ischemic stroke  $79.8.1 \pm 10.9 \mu\text{g/L}$  compared to the control group  $22.4 \pm 3.9 \mu\text{g/L}$  ( $P < 0.001$ ) (Figure 1). Serum IL-6 levels showed significant differences between the groups: control group:  $2.6 \pm 1.1 \text{ ng/L}$  to patients with ischemic stroke  $19.9 \pm 2.1 \text{ ng/L}$  ( $P < 0.001$ ) (Figure 2). Serum hepcidin levels were established in the previous study (Manolov *et al.*, 2014). Serum iron levels were increased in patients with ischemic stroke:  $39.8 \pm 4.7 \mu\text{mol/L}$  to  $20.5 \pm 5.4 \mu\text{mol/L}$  ( $P < 0.001$ ).




Figure 1. Measured serum hepcidin levels




Figure 2. Serum IL-6 concentrations in included groups

We found a significant correlation between serum iron levels and hepcidin concentration in both groups: patients with ischemic stroke ( $r = 0.620$ ,  $P < 0.001$ ) and in control group ( $r = 0.423$ ,  $P < 0.001$ ).

## DISCUSSION

Functional studies have demonstrated that hepcidin is the central regulator of systemic iron homeostasis by regulating ferroportin, the only protein known to release iron from cells

(Zhang and 2009). Ischemia-reperfusion increases hepcidin expression and down-regulates ferroportin expression in the cerebral cortex and the hippocampus (Ding *et al.*, 2001). It is known that inflammation up-regulates hepcidin expression and that cytokines are a major mediator of the inflammatory response. HIF-1 is one of the factors activated in early ischemia that can induce vascular endothelial growth factor, erythropoietin, etc. (Mabjeesh *et al.*, 2003). Previous studies have shown that iron chelators, can reduce injury caused by cardiac ischemia and reperfusion (Tang *et al.*, 2008) and cerebral ischemia (Hamrick *et al.*, 2005). In our study we found high serum hepcidin levels, elevated IL-6, iron and ferritin concentrations in patients with ischemic stroke.

## Conclusion

Recently, there are two pathways that contribute to iron overload in ischemic brain tissues as outlined. A) Ischemia increases the expression of cytokines that up-regulates hepcidin by the JAK/STAT3 pathway, which causes iron accumulation. And B) Ischemia up-regulates the HIF-1 $\alpha$  level, which leads to iron accumulation in the ischemic tissues. Our results indicate that serum hepcidin plays an important role for iron overload in cerebral ischemia.

## Acknowledgments

This project is implemented with the financial support of the Medical University - Sofia, "Grant 2012", Contract № 2/2012.

## REFERENCES

- Aki, H. S., Fujita, M., Yamashita, S., Fujimoto, K., Kumagai, K. *et al.* 2009. Elevation of jugular venous superoxide anion radical is associated with early inflammation, oxidative stress, and endothelial injury in forebrain ischemia–reperfusion rats. *Brain Res* 1292: 180–90.
- Amantea, D., Bageetta, G., Tassorelli, C., Mercuri, N. B. and Corasaniti, M. T. 2010. Identification of distinct cellular pools of interleukin-1beta during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. *Brain Research*, 1313: 11.
- Ding, H., Yan, C. Z., Shi, H., Zhao, Y. S., Chang, S. Y. *et al.* 2001. Hepcidin is involved in iron regulation in the ischemic brain. *PLoS ONE* 6(9): e25324
- Hamrick, S. E., McQuillen, P. S., Jiang, X., Mu, D., Madan, A. *et al.* 2005. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. *Neurosci Lett.*, 379: 96–100.
- Jia, J., Hu, Y. S., Yi Wu, Liu, G., Yu, H. X. *et al.* 2009. Pre-ischemic treadmill training affects glutamate and gamma aminobutyric acid levels in the striatal dialysate of a rat model of cerebral ischemia. *Life Sciences*, 84: 7.
- Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M. *et al.* 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. *Cancer Cell*, 3: 13.
- Manolov, V., Atanasova, B., Vasilev, V., Tzatchev, K. and Velizarova, M. 2014. ELISA method for serum hepcidin

- quantification in Bulgarian population. *Acta Medica Bulgarica*, 1, 22-29.
- Manolov, V., Atanasova, B., Velizarova, M., Vasilev, V. and Tzatchev, K. 2014. Serum hepcidin levels in Bulgarian population. *Clin. Lab*, 60:2001-2006.
- Moos, T., Rosengren Nielsen, T., Skjorringe, T. and Morgan, E. H. 2007. Iron trafficking inside the brain. *J. Neurochem.*, 103: 1730–1740.
- Nemeth, E., Tuttle, M. S., Powelson, J. Vaughn, M. B., Donovan, A. *et al.* 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*, 306: 2090–2093.
- Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X. *et al.* 2002. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J. Clin. Invest.*, 110: 1037–1044.
- Robach, P., Cairo, G., Gelfi, C., Bernuzzi, F., Pilegaard, H., Vigano, A., Santambrogio, P., Cerretelli, P., Calbet, J. A. L. Moutereau, S. and Lundby, C. 2007. Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. *Blood*. 109: 4724–4731.
- Sullivan, J. 2007. Macrophage iron, hepcidin, and atherosclerotic plaque stability. *Exp Biol Med*. 232: 1014–1020.
- Tacchini, L., Gammella, E., De Ponti, C., Recalcati, S. and Cairo, G. 2008. Role of HIF-1 and NF-kB Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals. *Journal of Biological Chemistry*, 283: 13.
- Tang, W. H., Wu, S., Wong, T. M., Chung, S. K., C, S. S. 2008. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. *Free Radic. Biol. Med*, 45: 9.
- Valenti, L., Swinkels, D. W., Burdick, L., Tjalsma, H., Bertelli, C., Fatta, C., Bignamini, D., Dongiovanni, P., Rametta, R., Motta, B. M., Fargion, S. and Fracanzani, A. L. 2009. Serum ferritin and hepcidin levels predict vascular damage in patients with nonalcoholic fatty liver disease. *Am. J/Hematol.*, 84: E236–E375.
- Viatte, L., Lesbordes-Brion, J. C., Lou, D. Q., Bennoun, M., Nicolas, G. *et al.* 2005. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. *Blood* 105: 4861–4864.
- Zhang, A. S. and Enns, C. A. 2009. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. *J. Biol. Chem.*, 284: 711–715.

\*\*\*\*\*